Ocugen (NASDAQ: OCGN) is one of 29 public companies in the “Surgical appliances & supplies” industry, but how does it compare to its competitors? We will compare Ocugen to related companies based on the strength of its risk, institutional ownership, valuation, earnings, dividends, analyst recommendations and profitability.
Valuation and Earnings
This table compares Ocugen and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ocugen Competitors||$1.39 billion||$142.47 million||17.54|
Insider and Institutional Ownership
56.3% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 19.7% of Ocugen shares are held by company insiders. Comparatively, 8.2% of shares of all “Surgical appliances & supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
Ocugen has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500. Comparatively, Ocugen’s competitors have a beta of 1.13, suggesting that their average share price is 13% more volatile than the S&P 500.
This table compares Ocugen and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations for Ocugen and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Surgical appliances & supplies” companies have a potential upside of 10.30%. Given Ocugen’s competitors higher possible upside, analysts plainly believe Ocugen has less favorable growth aspects than its competitors.
Ocugen Company Profile
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.